Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.50
Bid: 68.00
Ask: 75.00
Change: 0.00 (0.00%)
Spread: 7.00 (10.294%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Technology Enhancements

18 Jul 2018 07:00

RNS Number : 9050U
NetScientific PLC
18 July 2018
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Portfolio Company, Wanda Enhances Remote Patient Monitoring Platform with Improved Patient Adherence Features

 

London, UK - July 18th, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda's existing platform had been shown to predict 90% of patient-level adverse events up to 7 days in advance of their occurrence, and allows for virtual intervention to prevent such events.

 

The new enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalised reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech Application Programming Interface from Google that uses machine learning to deliver natural-sounding human voice automation. The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda's enhancements to its core technology mean that relationships between clinicians and patients will continue to improve, and will empower patients to take a more active role in the management of their diseases as well as increase their quality of life. We continue to see invaluable potential in Wanda and look forward to monitoring its progress in the coming months."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Wanda Expands Patient Management Platform with Enhanced Patient Adherence Features

San Francisco, CA - July 18th, 2018 - Wanda, Inc. announces a significant expansion of their market-leading Patient Management Platform with expansive new features to further improve patient care plan adherence. The Wanda solution, embedded with clinically proven machine learning, predicts 90% of patient-level adverse events seven days before they occur and then facilitates virtual interventions to keep them from occurring. The enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalized reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech API from Google that uses machine learning to deliver natural-sounding human voice automation.

The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence. Depending on the complexity of the care plan, as many as 40% of patients fail to adhere to treatment plans.1 Between $100 and $300 billion in avoidable health care costs have been attributed to non-adherence in the US annually, representing 3%-10% of total US healthcare costs.2

"Healthcare providers have been pleased with how the Wanda platform has positively impacted the relationship between patients and their clinical care teams. The clinicians are able better deliver on their mission to provide great care with meaning and timely insight. Patients are more engaged and in control of the care", stated William Bassett, Chief Commercialization Officer of Wanda, Inc.

A key driver in patient non-adherence is related to medications with adherence rates dropping to 20% for patients that are required to take thirteen or more medications per day.3 Patient non-adherence can be corrected by the patient with the appropriate support. The leading reason for non-adherence most commonly reported was forgetfulness by the patient.4 The Patient Reminder Suite in Wands is specifically designed help clinicians easily create, personalize, and schedule reminders for all types of care support needs including medication reminders, vitals, daily symptom survey questions, pending visits to the doctor or at home visits, and prompts to exercise. For patients that prefer to interact with Wanda using the interactive voice response model, the inclusion of the Google voice technology provides a warm sounding human voice adding even more satisfaction to the patient interaction.

"Wanda continues to expand on its mission to fuse cutting edge data science with clinical care management to solve the major roadblocks in care models," said Ahsan Samiee, Chief Technology Officer, Wanda, Inc. "The financial and clinical results achieved by customers continue to validate our belief that these approaches should be imbued across healthcare for the betterment of all."

 

1, 3. Martin L, Williams S, Haskard, DiMatteo M. 2005. The Challenge of Patient Adherence. Therapeutics and Clinical Risk Management. 2005; 189-199.

2, 4. Iuga A, McGuire M. 2014. Adherence and Health Care Costs. Risk Management and Healthcare Policy. 2104; 35-44.

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABBGDRRGBBGIR
Date   Source Headline
15th Jan 20207:00 amRNSBoard Change
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.